

Issue No 1:10

Zebrafish Models

Biomarkers & Pathology in Zebrafish Models

COPD

Obesity

Ataxia-Telangiectasia

NF1

Melanoma

Optic Neuritis


3 Great Questions in ALS Discovery by Dr. John Dirk Vestergaard Nieland

> Methods & Models Microglia

Translation Lessons from the Past

PENTAGRIT

www.pentagrit.com



Histology section of ALS zebrafish model showing cytoplasmic vacuolization, a hallmark feature of human ALS pathology.

Monthly Exclusives from **Pentagrit**



FEATURED SCIENTIST P3



METHODS & MODELS
- MICROGLIA *P6*



TRANSLATION LESSONS FROM THE PAST *P8*



BIOMARKERS & PATHOLOGY IN ZEBRAFISH MODELS *P11*

FEATURED SCIENTST



The Three Biggest Questions in ALS

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder with a profound impact on patients and families. Despite decades of research, therapeutic options remain extremely limited. In Europe, only a single approved medication—riluzole, introduced nearly 30 years ago—offers a modest extension of life expectancy by approximately three months. In the United States, two medications are available, with the recent addition of a therapy targeting patients with SOD1 mutations. These realities underscore the formidable challenges inherent in ALS drug development. The persistent lack of effective, broadly applicable therapies highlights the urgent need for innovative approaches that address the underlying mechanisms of disease progression. Therefore, the first question is:

1. What causes ALS?

Approximately 10% of ALS cases are linked to genetic mutations, notably in SOD1, TDP-43, FUS, and C9ORF72. The remaining 90% are sporadic, with risk influenced by unidentified genetic factors and environmental stressors—psychological, physical, toxicological, pathological, and dietary. These stressors can trigger a shift from glucose to lipid metabolism in the brain, leading to mitochondrial dysfunction, oxidative stress, and inflammation. This disrupts myelin maintenance, impairs neuronal signaling, and accelerates neurodegeneration.

Importantly, new research displays that metabolic changes precede symptom onset by years, highlighting the need for early intervention targeting neurometabolic pathways in ALS.

2. Why is there no effective treatment for ALS?

Current ALS treatments focus on isolated symptoms such as hypoxia or neuronal loss, yet by diagnosis, multiple pathological processes including inflammation, protein misfolding, myelin degradation, signaling disruption, and mitochondrial dysfunction are already established. Targeting a single symptom is insufficient; effective therapy requires intervention upstream disease at mechanisms or simultaneous targeting of multiple pathways, ideally before clinical onset.



MISSION

Neurometa Therapeutics was founded in 2019 to build on a decade of research undertaken by co-founder and CIO, Dr. John Nieland and his associates. While the challenge ahead is immense, our aim is clear: we want to cure ALS.

Dr. John Dirk Vestergaard Nieland CIO, Neurometa Therapeutics

Neurometa Therapeutics ApS Niels Jernes Vej 10 | 9220 Aalborg Ø | Denmark | Tel +45 2248 2276

Novi Science Park • Niels Jernes Vej 10 • Aalborg Ø • Denmark BioInnovation Institute • Ole Maaløes Vej 3 • 2200 Copenhagen N • Denmark

Website: www.neurometa.com

Metabolic inhibitors, particularly those modulating lipid metabolism, show promise. Neurometa Therapeutics is developing CPT1A inhibitors, inspired by the protective Arctic CPT1A mutation observed in both human and mouse studies. Early diagnosis remains challenging, but ongoing biomarker research is advancing this critical goal.

3. How can we more effectively test ALS drugs in pre-clinical models?

No single ALS model replicates the full spectrum of patient pathologies, necessitating the use of multiple models for comprehensive insight. Commonly used mouse models include those with SOD1, TDP-43, C9ORF72, and FUS mutations. SOD1 models lack TDP-43 aggregation but show effects, while downstream TDP-43 models exhibit aggregation yet miss key ALS features. C9ORF72 and FUS models often require environmental stressors to manifest disease, better reflecting sporadic ALS. Zebrafish models offer rapid disease progression and diverse pathology, complementing rodent studies. Integrating findings across these models is essential for advancing translational ALS research.

METHODS & MODELS

Microglia

BY SANDHIYA SEENIVASAN



icroglia, a specialized type of glial cell, serve as the p r i m a r y immune defence

within the central mechanism nervous system (CNS) and play a critical role in mediating neuroinflammatory responses. Zebrafish similar express mammalian microglial genes and are involved in addressing to detecting danger-associated signals, clearing apoptotic neurons, and modulating neuronal activity.

Tricaine methane sulfonate (MS-222) and immediately fixed in Dietrich's fixative for histological immunohistochemical and analysis of microglia. After fixation, undergo a dehydration process through a graded ethanol series (70%, 80%, 95%, and 99%) followed by clearance in xylene to remove alcohol. The cleared tissues are then embedded in paraffin wax, oriented dorsal side up to optimize sectioning of neural tissues, such as the optic tectum and hindbrain regions. Serial 7 µm sections are cut using a rotary microtome.

Methods:

Microglia in zebrafish larvae can be visualized using both Hematoxylin and Eosin (H&E) staining and Immunohistochemistry (IHC) techniques.

Zebrafish (Danio rerio) larvae at 9 days postfertilization (dpf) are euthanized in 4%





Figure 1 presents a histological image of zebrafish larvae brain at 20X magnification under a light microscope, stained with Hematoxylin and Eosin

ematoxylin and **Eosin** (H&E) staining, paraffin-embedded sections are deparaffinized in xylene, rehydrated through a descending ethanol series, and then stained with hematoxylin for 30 seconds, followed by a 1-minute rinse in RO water and eosin for 2 minutes. After staining, the sections are dehydrated through an ascending ethanol series, cleared in xylene, and mounted using DPX mounting medium. Slides are then imaged under a light microscope at 20x and 40x magnification.

by incubating the sections with a blocking solution. The sections are then incubated at 4°C for 24 hours with an anti-Iba1 antibody (primary antibody), for microglia detection.

Following primary antibody incubation, the sections washed with 1X TBS and then incubated with secondary a antibody, Donkey Anti-Goat IgG H&L, at room temperature for 30 minutes. After the secondary antibody incubation, the slides are washed and rehydrated using



(IHC) to detect microglia in zebrafish larvae is done by first by deparaffinization of tissue sections and rehydration before proceeding with antigen retrieval. Heat-induced epitope retrieval (HIER) or enzymatic digestion is used to unmask antigenic sites. Non-specific binding is minimized

xylene. Finally, sections are imaged under a fluorescence microscope at 20X and 40X magnification, focusing on the central brain region as the primary area of interest.



Figure 3 shows the experimenter observing the IHC slides of microglial cells under fluorescent microscope.

ABOUT THE AUTHOR

Sandhiya serves as a Research Assistant at Pentagrit Zebrafish CRO, actively working on neurological zebrafish models.

GET IN TOUCH

How can microglia quantification help my research?

EMAIL US AT:

sandhiya@pentagrit.com

TRANSLATION LESSONS FROM THE PAST

BY KEERTHANA RAJENDRAN



Clinical
Performance of
Dalzanemdor:

alzanemdor, a positive allosteric modula-

tor of the NMDA receptor, was developed to improve cognition in neuro- degenerative diseases such as Alzheimer's. Parkinson's, and Huntington's. Despite a rational and favourable safety profile, clinical consistently failed trials to demonstrate improvements on Symbol Digit Modalities (SDMT). SMDT is a neuropsychological screening tool that assesses cognitive processing speed, attention, visual scanning, and motor speed. Across all tested populations, dalzanemdor did not yield any measurable cognitive benefits. This outcome highlights that despite the use of a robust cognitive assessment tool the drug failed clinical trials. It does create the need for more predictive and functional evaluation in drug development.

Constraints in Translational Approaches:

The following key factors are likely to be contributing to dalzanemdor's lack of efficacy:

- Endpoint Mismatch: Clinical trials often measure limited cognitive functions, such as processing speed while leaving the functional deficits unassessed.
- Assumptions About Crossdiseases: NMDA receptor modulation was thought to provide uniform cognitive rescue for Huntington's, Parkinson's, and Alzheimer's diseases, ignoring the disease specific heterogeneity.
- Assumptions About Cross-diseases: NMDA receptor modulation was thought to provide uniform cognitive rescue for Huntington's, Parkinson's, and Alzheimer's diseases, ignoring the disease specific heterogeneity.
- Limited Early Functional Evaluation: The target engagement alone is not sufficient to measure all the cognitive outcomes, shows the importance of functional phenotype assessment in early stages of drug development.

FUNCTIONAL SCREENING IN ZEBRAFISH:

Cognitive and Behavioural Readouts:

different learning and memory behaviours, including T-maze navigation, predator avoidance, novel object recognition, associative learning and spatial memory.

These assays enable to evaluate diverse cognitive functions in real time. By utilziing these types of approaches to identify compounds that may show inconsistent effects on cognitive and executive functions such as learning and

memory before advancing to clinical trials.

Disease-Relevant Genetic Models:

Genetic models representing key features of neurodegenerative diseases:

- APP and tau for Alzheimer's disease
- Pink1 for Parkinson's disease
- HTT mutants for Huntington's disease

Testing compounds by using these models allows evaluation of disease specific efficacy of drugs, which provides early translational insights.

Lessons from Dalzanemdor's Development:

Several key lessons emerge:



Future Directions/ Strategic Outlook:

To enhance the potential of preclinical screening for Cognitive drugs:

- Integrating zebrafish cognitive tests which includes multiple functional areas should be applied.
- Utilizing disease specific models to compare the efficacy of drugs across specific models such as Alzheimer's, Parkinson's and Huntington's diseases.

 Inclusion of zebrafish model that carries human receptors to measure target modulation

ABOUT THE AUTHOR

Keerthana serves as a Research Assistant at Pentagrit Zebrafish CRO, actively working on translational research in zebrafish models.


Learn how zebrafish can help to classify your in vitro compounds? EMAIL US AT: keerthana@pentagrit.com

THERAPEUTIC PATHOLOGY & BIOMARKERS

In Zebrafish


Inflammation - COPD


Model - Cigarette Smoke Induction



Pathology:

Zebrafish models with dysfunction respiratory exhibit dyspnea impaired oxygen exchange, leading reduced to respiratory efficiency. Prednisone (45 pg) alleviates inflammation, improves gill function, and enhances oxygen uptake, restoring normal breathing patterns.






Biomarkers:

C-Reactive Protein (CRP) and TNF-a are elevated, inflammation promoting and tissue damage. Prednisone (45 pg) their suppresses expression, reducing inflammatory stress, stabilizing tissues, and improving overall respiratory function and breathing efficiency.


Metabolic - Obesity

Model - High Fat Diet



Pathology:

High-fat diet zebrafish show marked body weight gain due to excessive lipid accumulation and elevated triglyceride levels, reflecting disrupted lipid metabolism and metabolic stress. Rosuvastatin (6 µg) improves lipid handling, reduces adiposity, lowers triglycerides, and protects obesity-related against metabolic and cardiovascular complications.




Biomarkers:

Cholesterol levels are elevated in high-fat diet zebrafish, contributing to imbalance lipid and metabolic dysfunction. Leptin levels rise due to adiposity, increased causing leptin resistance. (6 μg) Rosuvastatin reduces cholesterol synthesis, lowers leptin, restores leptin sensitivity, improves and overall metabolic health and energy balance.


Rare - Ataxia Telangiectasia

Model - Atm-/-



Pathology:

Atm-/- zebrafish exhibit touch-evoked impaired response due to neuronal degeneration and defective DNA repair, resulting in loss of coordination and disability. motor (1.25pg)Dexamethasone neuroinflammareduces neuronal tion, supports partially survival, and function motor restores and sensory responsiveness in the model.




Biomarkers:

ATM protein levels significantly reduced Atm-/zebrafish. impairing DNA repair and contributing to neuronal degeneration. Neurofilament Light Chain levels elevated, indicating are axonal damage. Dexamethasone (1.25pg) supports ATM activity, reduces neurofilament release, and protects neurons. improving motor and sensory function.


Neuro – Neurofibromatosis Type 1

Model - NF1-/-



Pathology:

NF1-/- zebrafish exhibit touch-evoked impaired responses and heightened pain sensitivity due to neuronal hyperexcitability and MAPK/ERK pathway dysregulation. Mirdametinib (5pg) modulates signaling, reduces neuronal and stress, partially restores sensory function, improving tactile response and pain perception in the model.




Biomarkers:

BDNF levels are dysregulated NF1-/in zebrafish, impairing neuronal growth, survival, function. and synaptic **GFAP** elevated, is indicating glial activation neuroinflammation. and Mirdametinib (5pg) restores BDNF expression, reduces GFAP levels, and supports neuronal health, synaptic plasticity, overall sensory function in the model.


Tumor - Melanoma

Model - BRAFV600E-p53



Pathology:

BRAF^{V600E}-p53 lethargy zebrafish exhibit ectopic melanocyte proliferation, disrupting tissue architecture, and reduced locomotor activity due to tumor burden and cellular stress. Dacarbazine (20pg) limits abnormal melanogrowth, alleviates cyte tumor-induced stress, and partially restores normal locomotion and energy levels in the model.




Biomarkers:

expression Mitfa is elevated in BRAFV600E-p53 lethargy zebrafish, promoting melanocyte proliferation, while upregulated, **VEGFA** is driving angiogenesis and tumor progression. Dacar-(20pg) bazine reduces Mitfa and VEGFA levels, limiting melanocyte overgrowth, inhibiting vascularization. and controlling tumor development in the model.


Eye – Optic Neuritis

Model - ONC Injury



Pathology:

ONC-injured zebrafish exhibit impaired light sensitivity and reduced responsiveness to moving objects due to retinal neuron and optic nerve Prednisone damage. (45pg) reduces inflammation, protects neurons, and partially restores visual function, improving both perception light and motion detection in the model.



Biomarkers:

Tail writhing reflects visual impairment and neuronal distress in ONC-injured zebrafish, while AQP4 is upregulated, causing retinal edema and tissue stress. Prednisone (45pg) writhing, tail reduces normalizes AQP4 expression, alleviates inflammation, and supports retinal neuron survival and improved visual function.

CONTACT 15-

TOP 3 CSO Questions this Quarter.

- 1. How do we know long term safety of our drug and prevent an adverse effect scenario in clinical trials?
- 2.I got a few good compounds and need to select the best one for clinical development?
- 3.Can zebrafish tell me the outcome of a patient taking our drugs for more than 2 years?





